摘要
目的:比较广泛性焦虑伴失眠患者在抗焦虑治疗(艾司西酞普兰)初期合用或不用右佐匹克隆对患者失眠、焦虑症状的疗效与安全性。方法:将100例符合"中国精神障碍分类与诊断标准(第三版)"(CCMD-3)广泛性焦虑伴有失眠的患者随机分为试验组(52例)和对照组(48例)。试验组给予艾司西酞普兰合并右佐匹克隆治疗,对照组单用艾司西酞普兰治疗,观察期为8周。用汉密尔顿焦虑量表(HAMA)评定患者焦虑症状及疗效,用睡眠障碍量表(SDRS)评定失眠症状和疗效,同时用不良反应量表(TESS)和实验室检查评估治疗安全性。结果:试验组在治疗第1周末HAMA评分明显下降(P<0.01),对照组在第2周末HAMA评分明显下降(P<0.01),试验组在治疗后第1、2、4、6周末HAMA总分均低于对照组(P<0.05),第8周末差异无统计学意义(P>0.05)。2组在治疗后第1、2、4周末SDRS总分均低于治疗前(P<0.01)。试验组在第1、2、4周末SDRS总分均低于对照组(P<0.01)。试验组较对照组更易发生头痛、口苦、口干、恶心及困倦感(P<0.05)。结论:艾司西酞普兰合并右佐匹克隆治疗广泛性焦虑伴失眠,有助于快速改善患者的失眠和焦虑症状,但副反应相对明显。
AIM. To observe the efficacy and safety of escitalopram with or without eszopi- clone on the treatment of generalized anxiety dis- order with insomnia patients. METHODS： 100 patients who met the CCMD-3 criteria for gener- alized anxiety disorder with insomnia were ran- domly divided into the experimental group （n= 52） and the control group （n=48）. The experi- mental group were treated with escitalopram combining with eszopiclone, and the control group with escitalopram monotherapy. The trial lasted 8 weeks. The anxiety status and efficacy was evaluated with HAMA at the baseline, 1st, 2nd, 4th, 6th and 8th weekend respectively, the insomnia status with SDRS, and the safety with TESS and laboratory examination. RESULTS. The HAMA scores of the experimental group and the control group declined significantly by the end of 1st week （P〈0.01）and the end of 2nd week （P〈0.01）respectively, and the reduc- tion of HAMA scores of the experimental groupwas more significant than the control group at the end of 1st, 2nd, 4th and 6th weekend （P〈 0.05）, while there was no significant difference between the two groups at the end of 8th week- end （P〈0.05）. The SDRS scores of the experi- mental group declined significantly by the end of 1st week （P〈0.01）, and the reduction of SDRS scores of the experimental group was more sig- nificant than the control group at the end of 1st, 2nd, and 4th weekend （P〈0.01）. Side events happened more easily in the experimental group than in the control group such as headache, mouth pain, dry mouth, nausea and drowsiness （P^0.05） . CONCLUSION： Escitalopram with eszopiclone on the treatment of generalized anxi- ety disorder with insomnia patients contribute to a rapid improvement in insomnia and anxiety, but the side effects are relatively obvious.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2014年第1期54-57,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
